We are live on ! Find out more
DY

Dowling & Yahnke Portfolio holdings

AUM $2.15B
1-Year Est. Return 10.82%
This Fund
S&P 500
This Quarter Est. Return
+9.19%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
AUM
$1.3B
AUM Growth
+$93.3M
Cap. Flow
-$7.51M
Cap. Flow %
-0.58%
Top 10 Hldgs %
25.17%
Holding
390
New
85
Increased
121
Reduced
146
Closed
8

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$2.53M
2
DOCU
DocuSign
DOCU
+$1.16M
3
AAPL icon
Apple
AAPL
+$971K
4
MZTI
The Marzetti Company
MZTI
+$858K
5
MSFT icon
Microsoft
MSFT
+$723K

Sector Composition

Rank Sector Weight
1 Miscellaneous 24.98%
2 Technology 14.73%
3 Healthcare 13.63%
4 Financials 11.39%
5 Consumer Staples 9.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACWI icon
226
iShares MSCI ACWI ETF
ACWI
$33.3B
$597K 0.05%
7,538
PM icon
227
Philip Morris
PM
$299B
$582K 0.04%
6,837
-16
-0.2% -$1.32K
MUB icon
228
iShares National Muni Bond ETF
MUB
$45.5B
$535K 0.04%
+4,701
New +$535K
NEE icon
229
NextEra Energy
NEE
$171B
$534K 0.04%
8,816
+460
+6% +$26.9K
TFC icon
230
Truist Financial
TFC
$61.6B
$527K 0.04%
9,349
+790
+9% +$42.8K
VOO icon
231
Vanguard S&P 500 ETF
VOO
$1.03T
$526K 0.04%
1,778
+158
+10% +$44.7K
VCSH icon
232
Vanguard Short-Term Corporate Bond ETF
VCSH
$45B
$514K 0.04%
6,342
+1,084
+21% +$87.8K
DISH
233
DELISTED
DISH Network Corp.
DISH
$509K 0.04%
14,343
+4,585
+47% +$159K
BIV icon
234
Vanguard Intermediate-Term Bond ETF
BIV
$28.8B
$506K 0.04%
5,801
HII icon
235
Huntington Ingalls Industries
HII
$11.6B
$499K 0.04%
1,989
OXY icon
236
Occidental Petroleum
OXY
$59.1B
$499K 0.04%
12,106
-9,788
-45% -$392K
ONCT
237
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$495K 0.04%
6,265
-342
-5% -$35.4K
AGN
238
DELISTED
Allergan plc
AGN
$484K 0.04%
2,532
+304
+14% +$54.8K
IWN icon
239
iShares Russell 2000 Value ETF
IWN
$14.5B
$460K 0.04%
3,575
+60
+2% +$7.42K
RMD icon
240
ResMed
RMD
$34.7B
$457K 0.04%
2,952
-110
-4% -$15.9K
D icon
241
Dominion Energy
D
$57.7B
$446K 0.03%
5,382
-65
-1% -$5.31K
MCK icon
242
McKesson
MCK
$104B
$431K 0.03%
3,116
-90
-3% -$12.7K
IJK icon
243
iShares S&P Mid-Cap 400 Growth ETF
IJK
$10.8B
$430K 0.03%
7,224
+480
+7% +$27.5K
ZTS icon
244
Zoetis
ZTS
$32B
$420K 0.03%
3,174
+139
+5% +$17.3K
MO icon
245
Altria Group
MO
$115B
$418K 0.03%
8,370
+173
+2% +$8.16K
JCI icon
246
Johnson Controls International
JCI
$84.6B
$414K 0.03%
10,181
+1,022
+11% +$43.1K
GWPH
247
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$409K 0.03%
3,910
+4
+0.1% +$449
IJS icon
248
iShares S&P Small-Cap 600 Value ETF
IJS
$8.28B
$407K 0.03%
5,058
-496
-9% -$38.4K
DELL icon
249
Dell
DELL
$295B
$385K 0.03%
14,788
-805
-5% -$20.9K
XLY icon
250
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.1B
$385K 0.03%
6,134
-62
-1% -$3.77K

Similar funds

Dowling & Yahnke's Q4 2019 Portfolio in Review

As of Q4 2019, Dowling & Yahnke held 390 positions worth $1.3B, up 7.7% from $1.21B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Dowling & Yahnke's Q4 2019 filing shows 85 new, 121 increased, 146 reduced and 8 closed positions. Its largest new stake was iShares National Muni Bond ETF: 4,701 shares worth $535K. The largest sale was Celgene Corp, an estimated $2.53M.

By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, down from 25% a quarter earlier, followed by Technology and Healthcare.

  • Dowling & Yahnke's largest Q4 2019 buy was iShares National Muni Bond ETF: 4,701 shares worth $535K.
  • Dowling & Yahnke added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.6M increase.
  • Dowling & Yahnke's biggest Q4 2019 reduction was DocuSign, cutting an estimated $1.16M.
  • Dowling & Yahnke fully exited Celgene Corp in Q4 2019, selling an estimated $2.53M.
  • Dowling & Yahnke's ten largest holdings make up 25% of its $1.3B portfolio in Q4 2019.
  • Dowling & Yahnke opened 85 new positions and closed 8 in Q4 2019.
  • Dowling & Yahnke's portfolio value rose 7.7% quarter-over-quarter to $1.3B.

Based on Dowling & Yahnke's 13F filing for Q4 2019, filed 27 Jan 2020.